Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00846989 · ClinicalTrials.gov registry record · Phase 1
Efficacy, Tolerability and Safety of RKI983 (0.05% & 0.10%) vs Xalatan in Patients With POAG or Ocular Hypertension
A Phase 1 study of Glaucoma and Ocular Hypertension, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 276
- Enrollment target
- 20
- Study locations
NCT00846989 is a Phase 1 study of Glaucoma and Ocular Hypertension that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 276 participants, below the 908-participant average among 92 other Glaucoma trials with a reported enrollment target (70% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT00846989, a Phase 1 study of Glaucoma and Ocular Hypertension, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 276 participants
- Enrollment target
- 20
- Study locations
Study Summary
This purpose of this study is to access the efficacy, tolerability and safety of RKI983 (0.05% and 0.10%) ophthalmic solution bid versus once daily latanoprost 0.005%, in patients with POAG or ocular hypertension.
Conditions Studied
Interventions
- DRUG Latanoprost
- DRUG RKI983A
Study Locations (20)
California
- Novartis Investigative Site - Artesia
- Novartis Investigative Site - Inglewood
- Novartis Investigative Site - La Jolla
- Novartis Investigative Site - Poway
- Novartis Investigative Site - Stockton
Georgia
- Novartis Investigative Site - Atlanta
- Novartis Investigative Site - Morrow
- Novartis Investigative Site - Roswell
New York
- Novartis Investigative Site - Bethpage
- Novartis Investigative Site - Lynbrook
- Novartis Investigative Site - Rochester
Connecticut
- Novartis Investigative Site - Danbury
Hawaii
- Novartis Investigative Site - Kaneohe
Kansas
- Novartis Investigative Site - Topeka
Kentucky
- Novartis Investigative Site - Louisville
Louisiana
- Novartis Investigative Site - Bossier City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 276 participants |
| Start Date | 2009-01 |
| Est. Completion | 2009-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00846989
The ClinicalTrials.gov registry entry for NCT00846989 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 276 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 908-participant average among 92 other Glaucoma trials with a reported enrollment target (70% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Glaucoma appearing as the primary indexed condition, and to 2 interventions - of which Latanoprost is the first listed.
NCT00846989 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Georgia, New York.
Frequently Asked Questions
What is clinical trial NCT00846989 about?
NCT00846989 is a clinical study titled "Efficacy, Tolerability and Safety of RKI983 (0.05% & 0.10%) vs Xalatan in Patients With POAG or Ocular Hypertension". This purpose of this study is to access the efficacy, tolerability and safety of RKI983 (0.05% and 0.10%) ophthalmic solution bid versus once daily latanoprost 0.005%, in patients with POAG or ocular hypertension.
What is the current status of trial NCT00846989?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 276 participants. The study started on 2009-01. Estimated completion is 2009-04.
What conditions does trial NCT00846989 study?
This clinical trial studies the following conditions: Glaucoma, Ocular Hypertension.
What interventions are being tested in trial NCT00846989?
The interventions under investigation include: Latanoprost (DRUG), RKI983A (DRUG).
Who is sponsoring clinical trial NCT00846989?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00846989 being conducted?
This trial has 20 study locations across California, Connecticut, Georgia, Hawaii, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glaucoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Topical Insulin for Glaucoma
RECRUITING · Phase 1
-
Safety Assessment of T4090 Eye Drops in Ocular Hypertensive or Glaucomatous Patients.
ACTIVE NOT RECRUITING · Phase 1
-
Evaluation of the Bimatoprost Implant System Used in Combination With the SpyGlass Intraocular Lens Compared to Timolol Ophthalmic Solution
ACTIVE NOT RECRUITING · Phase 1
-
A Dose-Escalation Study Designed to Evaluate the Tolerability, Safety, Pharmacokinetics (PK), and Efficacy of Chronic Topical Ocular Application of INO-8875 in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma
COMPLETED · Phase 1
-
Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt
COMPLETED · Phase 1
-
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5093151 in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.